Mirum Pharmaceuticals vs Tarsus Pharmaceuticals
Mirum Pharmaceuticals is the larger business, with $521m of revenue in fiscal 2025 against $451m for Tarsus Pharmaceuticals (1.2 times as much). Tarsus Pharmaceuticals grew faster (146.7% against 54.7%). Mirum Pharmaceuticals kept more of each dollar of sales as profit: a net margin of -4.5% against -14.7%. Tarsus Pharmaceuticals carries less debt relative to equity (21.8% against 98.4%).
| Latest fiscal year | Mirum PharmaceuticalsMIRM, 2025 | Tarsus PharmaceuticalsTARS, 2025 |
|---|---|---|
| Revenue | $521m | $451m |
| Revenue growth | 54.7% | 146.7% |
| Net income | −$23.4m | −$66.4m |
| Operating margin | -4.2% | -15.7% |
| Net margin | -4.5% | -14.7% |
| Return on equity | -8.6% | -23.4% |
| Free cash flow | $54.9m | −$22.3m |
| Cash | $297m | $184m |
| Total debt | $310m | $75.0m |
| Debt to equity | 98.4% | 21.8% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 372 | 370 |
| Market value | $5.61bn | $3.09bn |
| Price vs our value range | — | — |
| Moat score | 10 (Weak) | 14 (Weak) |
| Insider trades, 12 months | 1 buys, 59 sales | 0 buys, 59 sales |